edotreotide has been researched along with Thyroid Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogova, S; Huchet, V; Kerrou, K; Michaud, L; Montravers, F; Nataf, V; Talbot, JN | 1 |
| Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; Grana, C; Handkiewicz-Junak, D; Lopera Sierra, M; Mäcke, HR; Mazzetta, C; Paganelli, G; Rocca, P | 1 |
| Andreas, J; Bockisch, A; Brandt-Mainz, K; Bruns, C; Görges, R; Kahaly, G; Mäcke, H; Müller-Brand, J; Walgenbach, S | 1 |
| Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Pless, M; Schumacher, T; Waldherr, C | 1 |
| Bockisch, A; Görges, R; Kahaly, G; Mäcke, H; Müller-Brand, J; Roser, HW | 1 |
| Cybulla, M; Otte, A; Weiner, SM | 1 |
1 review(s) available for edotreotide and Thyroid Neoplasms
| Article | Year |
|---|---|
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Lung Neoplasms; Multimodal Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Recurrence; Sensitivity and Specificity; Thyroid Neoplasms; Tomography, Emission-Computed, Single-Photon | 2013 |
1 trial(s) available for edotreotide and Thyroid Neoplasms
| Article | Year |
|---|---|
Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
Topics: Adult; Aged; Anemia; Female; Humans; Kidney Diseases; Lymphopenia; Male; Middle Aged; Octreotide; Pilot Projects; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Survival Analysis; Thyroid Neoplasms | 2001 |
4 other study(ies) available for edotreotide and Thyroid Neoplasms
| Article | Year |
|---|---|
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Topics: Adult; Aged; Carcinoma, Medullary; Female; Humans; Male; Middle Aged; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Retrospective Studies; Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2004 |
[Somatostatin receptor status in non-medullary thyroid carcinoma].
Topics: Adenocarcinoma, Follicular; Adult; Aged; Autoradiography; Carcinoma, Papillary; Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Male; Middle Aged; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Thyroid Neoplasms; Tomography, Emission-Computed; Yttrium Radioisotopes | 1999 |
Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2001 |
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe?
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Medullary; Humans; Hypertension, Renal; Kidney Failure, Chronic; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes | 2002 |